#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Dementia Alzheimer's type Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dermatitis atopic Breast cancer metastatic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Aplastic anaemia Obliterative bronchiolitis Leiomyosarcoma Non-Hodgkin's lymphoma Adenomatous polyposis coli Aspergillus infection Alagille syndrome Primary amyloidosis Congenital hypotransferrinaemia Acute graft versus host disease in liver Lip and/or oral cavity cancer Methylmalonic acidaemia Synovitis Brain stem glioma Cholangiocarcinoma More trials…

    Learn about Rare Diseases

    Glomerulonephritis membranoproliferative – Basic Information Waldenstrom’s macroglobulinaemia refractory – Trials in Disease Glomerulonephritis membranous – Treatment Adrenogenital syndrome – Treatment Lymphangioma VEXAS syndrome Pituitary-dependent Cushing’s syndrome Angiosarcoma – Trials in Disease Crigler-Najjar syndrome – Diagnostics Inclusion body myositis – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Etoricoxib Buparlisib Saxagliptin Izokibep PROMESTRIENE Dextromethadone Hydrochloride Rilpivirine Hydrochloride Iph5201 Sym023 Trastuzumab Cefixime Temsirolimus Naloxegol Oxalate ABBV-8736 Glepaglutide Cetrorelix Dorzolamide Hydrochloride Letrozole Allopurinol Remibrutinib More therapies…

    Learn about Your Condition

    Haemoglobinuria Sinusitis bacterial Hyperhidrosis Huntington's disease Major depression Lysosomal storage disorder Type 2 diabetes mellitus Colorectal adenoma Binge eating Biotinidase deficiency Apheresis Primary adrenal insufficiency Crohn's disease Rectal cancer recurrent Thalassaemia beta More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Vaccine

  • Study of Cemiplimab, Platinum and Gemcitabine in Treatment‑Naïve Patients with Advanced Squamous Non‑Small Cell Lung Cancer

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • Squamous cell carcinoma of lung
    Investigated Drugs:
    • Cemiplimab
    Italy

  • A Phase 2 Study of Methylenedioxymethamphetamine‑Assisted Therapy in Young Adults (18‑25) with Chronic Treatment‑Resistant Major Depressive Disorder

    Not yet recruiting

    2 1 1
    Investigated Diseases:
    • Major depression
    Norway

  • Effect of dry extract from Psilocybe cubensis (15‑25:1), extraction solvent methanol, with psychotherapy versus basic support on depressive symptoms in adults with depression

    Not yet recruiting

    2 1 1
    Investigated Diseases:
    • Depression
    Investigated Drugs:
    • Dry Extract From Psilocybe Cubensis (15-25:1), Extraction Solvent: Methanol
    Denmark

  • Feasibility Study of Fluorescence Bronchoscopy Using bevacizumab-800CW in Patients with Suspected Lung Cancer

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • Lung neoplasm malignant
    Investigated Drugs:
    • Bevacizumab
    The Netherlands

  • A Randomized Controlled Trial of Cannabidiol vs Placebo Augmentation in Patients with First Episode Psychosis

    Not yet recruiting

    3 1 1
    Investigated Drugs:
    • Cannabidiol
    Austria Germany Greece Italy The Netherlands Spain

  • Study of IDE849, IDE‑161 and durvalumab evaluating safety and efficacy in patients with DLL3‑positive tumors including small cell lung cancer

    Not yet recruiting

    1 1 1 1
    Investigated Diseases:
    • Neoplasm
    Investigated Drugs:
    • Durvalumab
    France Spain
Previous Page
1 … 684 685 686 687 688 … 1,657
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!